Fate Therapeutics Inc expected to post a loss of 77  cents a share - Earnings Preview

Fate Therapeutics

03/05/2022 03:05

* Fate Therapeutics Inc  FATE.OQ   FATE.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 4. 
    * The San Diego California-based  company is expected to
report  a
15.7% decrease in revenue to $9.397 million from $11.14 million
a year ago, according to the mean estimate from 15 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Fate Therapeutics
Inc is
for a loss of 77 cents per share. For the same quarter last
year, the company reported a loss of 48 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 17 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.9%
in the last three months. ​
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $90​, above​ its last closing price of $29.77. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.65       -0.67      -0.72     Missed  -8
 Sep. 30 2021  -0.59       -0.58      -0.45     Beat    22.6
 Jun. 30 2021  -0.54       -0.53      -0.58     Missed  -10​
 Mar. 31 2021  -0.45       -0.43      -0.48     Missed  -10.9
 ​​Dec.        -0.40       -0.39      -0.61     Missed  -55.2
 31 2020                                                
 Sep. 30 2020  -0.36       -0.36      -0.68     Missed  -87.5​
 Jun. 30 2020  -0.27       -0.27      -0.35     Missed  -29.6
 Mar. 31 2020  -0.39       -0.39      -0.44     Missed  -13.1
 This summary was machine generated May 3 at 02:05 GMT.  All
figures in US dollars  unless otherwise stated